PEG-functionalized nanoparticles as carriers of chemotherapeutics agents have been explored with
notable successes in preclinical and clinical stages of cancer treatment, with some already approved by FDA,
namely PEGylated liposomes and polymers. Half-life extension of therapeutic agents through PEGylation process
improves their pharmacokinetic (PK) profiles, thereby reducing their dosing frequency. Protein corona composition
of PEGylated nanoparticles (NPs) confers a tremendous influence on their surface characteristics which
directly impact tumor accumulation and clearance properties of the drugs. By controlling the size and complexity
of PEG molecules, as well as by attaching targeting moieties, the surface characteristics of NPs can be manipulated
to improve their tumor uptake without sacrificing the circulation time. This review focuses on design and
applications of PEGylated NPs for tumor targeted drug delivery in animal models and clinical setting.
Keywords: PEGylation, protein corona, pharmacokinetics, biodistribution, nanoparticles, tumor regression, tumor accumulation.
Rights & PermissionsPrintExport